Results presented from some studies are a signal of an active area of research which is investigating not only immune checkpoint inhibitors but also vaccines and cellular therapies, although there are no immunotherapy treatments currently approved.
Results from early-phase studies reveal potential for a new cancer vaccine and adaptive immunotherapy
Three studies support the use of NGS to better understand the molecular drivers of this brain tumour, but effective targeted treatments are still lacking
Research is getting closer to the development of patient-specific tailored treatment approaches for brain tumours, thanks to increased understanding of the tumour microenvironment, including the critical importance of the immune system
Results show it may help to define more homogeneous subgroups of patients with grade II–III glioma for more timely and effective cancer care
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.